Bristol-Myers Squibb Acquires License from Novo Nordisk

Mar 24, 2015

Bristol-Myers Squibb Company signed an agreement with Novo Nordisk under which BMS will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases, according to a press release. Terms of the agreement were not announced.

Bristol-Myers Squibb says the agreement supports its long-standing commitment to immunoscience, a core therapeutic area with multiple innovative drug candidates in development to target immune-mediated diseases with high unmet medical needs.

Read the full release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments